Technology ID
TAB-4954
Broadly Neutralizing Antibodies Targeting the V1V2 Epitope of HIV-1 Env from CAPRISA Donor CAP 256: Therapeutic Potential and Preferential Clade A and Clade C Neutralization
E-Numbers
E-147-2015-0
Lead Inventor
Abdool Karim, Salim
Lead IC
NIAID
Co-Inventors
Morris, Lynn
Williamson, Carolyn
Shapiro, Lawrence
Gorman, Jason
Kwong, Peter
Doria-Rose, Nicole
Mascola, John
ICs
NIAID
Applications
Therapeutics
Therapeutic Areas
Infectious Disease
Development Stages
Discovery
Research Products
Research Equipment
Antibodies
This technology encompasses the discovery of broadly neutralizing antibodies against HIV-1, derived from the CAPRISA Donor CAP 256. These antibodies target the V1V2 epitope of the virus envelope and exhibit a high level of neutralization, particularly against Clade A and Clade C subtypes. With potential applications in therapeutic or prophylactic interventions against HIV-1, this discovery represents a significant advancement in the field, offering a novel approach to combating the virus.
Commercial Applications
The discovery of broadly neutralizing antibodies targeting the V1V2 epitope of HIV-1 from CAPRISA Donor CAP 256 has significant potential applications in the field of HIV treatment and prevention. These antibodies could be developed into novel therapeutic agents for HIV-infected individuals, offering a more targeted and potentially more effective treatment option. Additionally, they could be used in prophylactic interventions, such as pre-exposure prophylaxis (PrEP), to prevent HIV infection in high-risk populations. Furthermore, these antibodies could be valuable tools for HIV vaccine development, serving as templates for designing vaccine candidates that elicit similar broadly neutralizing antibodies in individuals. Overall, this discovery opens up new possibilities for combating HIV and improving the lives of those affected by the virus.
Competitive Advantages
The broadly neutralizing antibodies discovered from CAPRISA Donor CAP 256 offer several competitive advantages over existing approaches. These antibodies demonstrate a remarkable ability to neutralize a broad range of HIV-1 variants, including challenging Clade A and Clade C subtypes, which are prevalent in many regions heavily affected by HIV. This specificity and potency make them promising candidates for therapeutic or prophylactic interventions against HIV-1. Additionally, the discovery of these antibodies represents a unique approach that could potentially overcome the limitations of current treatments, providing a new avenue for combating the virus.
Licensing Contact: